| Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. | |
| | |
MedLine Citation:
|
PMID: 16143698 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: The benefit of clopidogrel pretreatment before percutaneous coronary intervention (PCI) remains debated and its use has not been universally adopted. OBJECTIVE: To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events. DESIGN, SETTING, AND PARTICIPANTS: The PCI-Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) study was a prospectively planned analysis of the 1863 patients undergoing PCI after mandated angiography in CLARITY-Thrombolysis in Myocardial Infarction (TIMI) 28, a randomized, double-blind, placebo-controlled trial of clopidogrel in patients receiving fibrinolytics for STEMI. Patients were enrolled at 319 sites in 23 countries from February 2003 through October 2004. INTERVENTIONS: Patients received aspirin and were randomized to receive either clopidogrel (300 mg loading dose, then 75 mg once daily) or placebo initiated with fibrinolysis and given until coronary angiography, which was performed 2 to 8 days after initiation of the study drug. For patients undergoing coronary artery stenting, it was recommended that open-label clopidogrel (including a loading dose) be administered after the diagnostic angiogram. MAIN OUTCOME MEASURES: The primary outcome was the incidence of the composite of cardiovascular death, recurrent MI, or stroke from PCI to 30 days after randomization. Secondary outcomes included MI or stroke before PCI and the aforementioned composite from randomization to 30 days. RESULTS: Pretreatment with clopidogrel significantly reduced the incidence of cardiovascular death, MI, or stroke following PCI (34 [3.6%] vs 58 [6.2%]; adjusted odds ratio [OR], 0.54 [95% CI, 0.35-0.85]; P = .008). Pretreatment with clopidogrel also reduced the incidence of MI or stroke prior to PCI (37 [4.0%] vs 58 [6.2%]; OR, 0.62 [95% CI, 0.40-0.95]; P = .03). Overall, pretreatment with clopidogrel resulted in a highly significant reduction in cardiovascular death, MI, or stroke from randomization through 30 days (70 [7.5%] vs 112 [12.0%]; adjusted OR, 0.59 [95% CI, 0.43-0.81]; P = .001; number needed to treat = 23). There was no significant excess in the rates of TIMI major or minor bleeding (18 [2.0%] vs 17 [1.9%]; P>.99). CONCLUSIONS: Clopidogrel pretreatment significantly reduces the incidence of cardiovascular death or ischemic complications both before and after PCI and without a significant increase in major or minor bleeding. These data add further support to the early use of clopidogrel in STEMI and the strategy of routine clopidogrel pretreatment in patients undergoing PCI. |
| | |
Authors:
|
Marc S Sabatine; Christopher P Cannon; C Michael Gibson; Jose L López-Sendón; Gilles Montalescot; Pierre Theroux; Basil S Lewis; Sabina A Murphy; Carolyn H McCabe; Eugene Braunwald; |
Related Documents
:
|
16580518 - St-segment elevation myocardial infarction: recommendations on triage of patients to he... 23178608 - Atypical variant stress (takotsubo) cardiomyopathy associated with gastrointestinal ill... 19632518 - Predictors of no-reflow after percutaneous coronary intervention for culprit lesion wit... 23195488 - Phytotherapy in heart failure. 19937468 - Methods from the theory of random heterogeneous media for quantifying myocardial morpho... 23386948 - Hemorrhagic cardioembolic stroke secondary to a left ventricular thrombus: a therapeuti... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. Date: 2005-09-04 |
Journal Detail:
|
Title: JAMA : the journal of the American Medical Association Volume: 294 ISSN: 1538-3598 ISO Abbreviation: JAMA Publication Date: 2005 Sep |
Date Detail:
|
Created Date: 2005-09-14 Completed Date: 2005-09-15 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7501160 Medline TA: JAMA Country: United States |
Other Details:
|
Languages: eng Pagination: 1224-32 Citation Subset: AIM; IM |
Affiliation:
|
The Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA. msabatine@partners.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Transluminal, Percutaneous Coronary* Aspirin / therapeutic use Female Humans Male Middle Aged Myocardial Infarction / drug therapy, therapy* Platelet Aggregation Inhibitors / administration & dosage*, therapeutic use Thrombolytic Therapy Ticlopidine / administration & dosage, analogs & derivatives*, therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
R01 HL072879/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel |
| Comments/Corrections | |
Comment In:
|
ACP J Club. 2006 Mar-Apr;144(2):29
[PMID:
16539344
]
JAMA. 2005 Sep 14;294(10):1271-3 [PMID: 16143697 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisopr...
Next Document: Evaluation of a modified Huddart/Bodenham scoring system for assessment of maxillary arch constricti...